1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Open-Angle Glaucoma Therapeutics Market: About this market
Open-angle glaucoma is a condition of the eye that leads to progressive atrophy of the optic nerve in the presence of an open angle. This open-angle glaucoma therapeutics market analysis considers sales from both prostaglandin analogs (PGAs) and non-prostaglandin analogs (NPAs). Our analysis also considers the sales of open-angle glaucoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the PGAs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as first-line treatment option and increasing use of a combination of PGAs with other drugs will play a significant role in the PGAs segment to maintain its market position. Also, our global open-angle glaucoma therapeutics market report looks at factors such as promising pipeline and recent approvals and increasing demand for combination drugs. However, uncertainties in the advances in glaucoma surgery, low patient adherence of topical medications, and asymptomatic nature of open-angle glaucoma may hamper the growth of the glaucoma therapeutics industry over the forecast period.
Global Open-Angle Glaucoma Therapeutics Market: Overview
Increasing demand for combination drugs
Combination drugs aim at different targets or pathways to combat the disease with minimal adverse effects. Moreover, they also improve tolerability, as two compounds can be employed below their individual dose thresholds. The demand for combination drugs will increase owing to their advantages, which will subsequently lead the market to grow at a CAGR of over 4% during the forecast period.
Strategic alliances
The high prevalence of open-angle glaucoma and requirement of novel medication led pharmaceutical companies to focus on the development of new drugs to treat open-angle glaucoma. During the development of new drugs, numerous companies are forming collaborations with other companies, which will speed up the development process and also increase the investments in research. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global open-angle glaucoma therapeutics market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading open-angle glaucoma therapeutics companies, that include Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.
Also, the open-angle glaucoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Open-angle glaucoma is a condition of the eye that leads to progressive atrophy of the optic nerve in the presence of an open angle. This open-angle glaucoma therapeutics market analysis considers sales from both prostaglandin analogs (PGAs) and non-prostaglandin analogs (NPAs). Our analysis also considers the sales of open-angle glaucoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the PGAs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as first-line treatment option and increasing use of a combination of PGAs with other drugs will play a significant role in the PGAs segment to maintain its market position. Also, our global open-angle glaucoma therapeutics market report looks at factors such as promising pipeline and recent approvals and increasing demand for combination drugs. However, uncertainties in the advances in glaucoma surgery, low patient adherence of topical medications, and asymptomatic nature of open-angle glaucoma may hamper the growth of the glaucoma therapeutics industry over the forecast period.
Global Open-Angle Glaucoma Therapeutics Market: Overview
Increasing demand for combination drugs
Combination drugs aim at different targets or pathways to combat the disease with minimal adverse effects. Moreover, they also improve tolerability, as two compounds can be employed below their individual dose thresholds. The demand for combination drugs will increase owing to their advantages, which will subsequently lead the market to grow at a CAGR of over 4% during the forecast period.
Strategic alliances
The high prevalence of open-angle glaucoma and requirement of novel medication led pharmaceutical companies to focus on the development of new drugs to treat open-angle glaucoma. During the development of new drugs, numerous companies are forming collaborations with other companies, which will speed up the development process and also increase the investments in research. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global open-angle glaucoma therapeutics market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading open-angle glaucoma therapeutics companies, that include Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.
Also, the open-angle glaucoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORKPART 11: MARKET TRENDS
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits:
Note: Product cover images may vary from those shown
The following companies are recognised as the key players in the global open-angle glaucoma therapeutics market: Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of the strategic alliances”
According to the report, one of the major drivers for this market is the Increasing demand for combination drugs.
Further, the report states that one of the major factors hindering the growth of this market is the advances in glaucoma surgery.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of the strategic alliances”
According to the report, one of the major drivers for this market is the Increasing demand for combination drugs.
Further, the report states that one of the major factors hindering the growth of this market is the advances in glaucoma surgery.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Aerie Pharmaceuticals Inc.
- Allergan Plc
- Bausch Health Companies Inc.
- Novartis AG
- Pfizer Inc.
Note: Product cover images may vary from those shown
